Transcatheter Embolization and Occlusion Devices Market: Snapshot
The transcatheter embolization and occlusion (TEO) devices market has witnessed strong growth in the past few years due to the rising focus on innovation, resulting in higher product approvals and product launches globally. The market is also characterized by significant research and development leading to several technological innovations.
In terms of revenue, the global TEO devices market was valued at US$2.4 bn in 2015 and is projected to reach US$4.8 bn by 2024 at a CAGR of 7.9% therein. In terms of volume, the global market is anticipated to register a CAGR of 8.1% from 2016 to 2024.
High Prevalence of Obesity Drives Use of TEO Devices in Treating Peripheral Vascular Diseases
Embolization coils are the leading products in the market, as these are one of the oldest embolization products available in the market. However, the embolization particles and flow diverter devices segments are expected to record a high CAGR during the forecast period.
Based on application, the peripheral vascular disease segment dominates the transcatheter embolization and occlusion devices market. This segment is expected to continue its lead through 2024 due to a growing geriatric population, changing lifestyles leading to a high prevalence of obesity, and the rising demand for minimally-invasive procedures. However, the oncology segment is expected to record a high CAGR during the forecast period due to the rising prevalence of cancer across the globe.
By end use, the hospitals segment captured a considerable market share and is likely to remain a key segment in the transcatheter embolization and occlusion devices market, expanding at a high CAGR during the forecast period.
Booming Medical Tourism Industry Contributing toward Growth of APAC TEO Devices Market
North America accounted for a major share in the global transcatheter embolization and occlusion devices market in 2015 due to the presence of leading market players in the region. Most of these companies operating in the region have made a series of strategic acquisitions, which contributes to an increase in their market share. The growing prevalence of cancer in the region is one of the primary factors contributing to the growth of the transcatheter embolization and occlusion devices market. According to the American Cancer Society, over 1,658,370 new cancer cases were diagnosed and 589,430 cancer deaths reported in the U.S. in 2015 alone. Well-established reimbursement policies by private or public organizations for TEO devices is also a major factor spurring the adoption of these devices North America.
Get Free Sample Research Report:
The transcatheter embolization and occlusion devices market in Asia Pacific is expected to expand at a high CAGR during the forecast period. A large patient pool and rising awareness about transcatheter embolization procedures are the key factors driving the adoption of TEO devices in the region. The booming medical tourism industry, driven by rising government support and the incorporation of different schemes by the government to avail better treatment for patients, is also expected to propel the transcatheter embolization and occlusion devices market. An increase in the number of localized manufacturers and the strengthening of the distribution network in Asia Pacific due to a rapidly growing economy offer significant benefits for market players as far as investments are concerned. A surge in the prevalence of neurovascular diseases and cancer in several countries across Asia Pacific is projected to fuel the market in the coming years.
Major players operating in the transcatheter embolization and occlusion devices market include Abbott Laboratories, Boston Scientific Corporation, BTG plc, Cook Medical, Inc., Edwards Lifesciences, Johnson & Johnson, Medtronic plc, Merit Medical Systems, Inc., Penumbra, Inc., Pfizer, Inc., Sirtex Medical Limited, St. Jude Medical, Inc., Stryker Corporation, and Terumo Corporation.